JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 25, 2008; DOI: 10.1124/jpet.108.142083


0022-3565/08/3271-277-286$20.00
JPET 327:277-286, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.142083v1
327/1/277    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linden, A.-M.
Right arrow Articles by Korpi, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linden, A.-M.
Right arrow Articles by Korpi, E. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DIAZEPAM
*FLURAZEPAM
*PENTOBARBITAL
*PROPOFOL

BEHAVIORAL PHARMACOLOGY

K+ Channel TASK-1 Knockout Mice Show Enhanced Sensitivities to Ataxic and Hypnotic Effects of GABAA Receptor Ligands

Anni-Maija Linden, M. Isabel Aller, Elli Leppä, Per H. Rosenberg, William Wisden, and Esa R. Korpi

Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland (A.-M.L., E.L., E.R.K.); Instituto de Neurociencas de Alicante, Consejo Superior de Investigaciones Cientificas-Universidad Miguel Hernández, Sant Joan d'Alacant, Spain (M.I.A.); Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom (W.W.); and Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, Finland (P.H.R.)

TASK two-pore-domain leak K+ channels occur throughout the brain. However, TASK-1 and TASK-3 knockout (KO) mice have few neurological impairments and only mildly reduced sensitivities to inhalational anesthetics, contrasting with the anticipated functions and importance of these channels. TASK-1/-3 channel expression can compensate for the absence of GABAA receptors in GABAA {alpha}6 KO mice. To investigate the converse, we analyzed the behavior of TASK-1 and -3 KO mice after administering drugs with preferential efficacies at GABAA receptor subtypes: benzodiazepines (diazepam and flurazepam, active at {alpha}{gamma}2, {alpha}{gamma}2, {alpha}{gamma}2, and {alpha}{gamma}2 subtypes), zolpidem ({alpha}{gamma}2 subtype), propofol (β2–3-containing receptors), gaboxadol ({alpha}{delta} and {alpha}{delta} subtypes), pregnanolone, and pentobarbital (many subtypes). TASK-1 KO mice showed increased motor impairment in rotarod and beam-walking tests after diazepam and flurazepam administration but not after zolpidem. They also showed prolonged loss of righting reflex induced by propofol and pentobarbital. Autoradiography indicated no change in GABAA receptor ligand binding levels. These altered behavioral responses to GABAergic drugs suggest functional up-regulation of {alpha}2β2/3{gamma}2 and {alpha}3β2/3{gamma}2 receptor subtypes in TASK-1 KO mice. In addition, female, but not male, TASK-1 KO mice were more sensitive to gaboxadol, suggesting an increased influence of {alpha}{delta} or {alpha}{delta} subtypes. The benzodiazepine sensitivity of TASK-3 KO mice was marginally increased. Our results underline that TASK-1 channels perform such key functions in the brain that compensation is needed for their absence. Furthermore, because inhalation anesthetics act partially through GABAA receptors, the up-regulation of GABAA receptor function in TASK-1 KO mice might mask TASK-1 channel's significance as a target for inhalation anesthetics.


Received June 10, 2008; accepted July 24, 2008.

Address correspondence to: Dr. Anni-Maija Linden, Institute of Biomedicine, Pharmacology, University of Helsinki, POB 63 (Haartmaninkatu 8), 00014 University of Helsinki, Finland. E-mail: anni-maija.linden{at}helsinki.fi







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.